University of Kansas Cancer Center Post San Antonio Review


 

What's New in HER2+ MBC Targeted Therapy: Efficacy Analysis of Oral HER2-TKIs Tucatinib & Neratinib

380 views
March 5, 2021
Comments 0
Login to view comments. Click here to Login